Daptomycin
- Generic Name
- Daptomycin
- Brand Names
- Cubicin, Dapzura, Daptomycin Hospira
- Drug Type
- Small Molecule
- Chemical Formula
- C72H101N17O26
- CAS Number
- 103060-53-3
- Unique Ingredient Identifier
- NWQ5N31VKK
- Background
Daptomycin is a cyclic lipopeptide antibacterial agent with a broad spectrum of activity against Gram-positive bacteria, including methicillin-susceptible and -resistant Staphylococcus aureus (MSSA/MRSA) and vancomycin-resistant Enterococci (VRE). Chemically, daptomycin comprises 13 amino acids, including several non-standard and D-amino acids, with the C-te...
- Indication
Daptomycin is indicated for the treatment of complicated skin and skin structure infections (cSSSI) in patients one year of age and older. It is also indicated for the treatment of Staphylococcus aureus bloodstream infections (bacteremia) in patients one year of age and older, including in adult patients with right-sided infective endocarditis.
...
- Associated Conditions
- Complicated Skin and Skin Structure Infection, Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia)
- Associated Therapies
- -
Study of Daptomycin in Subjects Undergoing Surgery for Osteomyelitis Associated With an Infected Prosthetic Caused by Staphylococci
- Conditions
- Interventions
- First Posted Date
- 2007-01-30
- Last Posted Date
- 2018-01-31
- Target Recruit Count
- 75
- Registration Number
- NCT00428844
- Locations
- 🇺🇸
Dartmouth-Hitchcock Medical center, Lebanon, New Hampshire, United States
🇷🇺Federal Healthcare Institute "Novosibirsk Scientific Research Institute of Traumatology and Orthopedy Rosmeditechnology", Novosibirsk, Russian Federation
🇺🇸Gundersen Clinic, LTD, La Crosse, Wisconsin, United States
Phase 2 Safety and Efficacy Study of Daptomycin in Complicated Skin and Skin Structure Infections
- Conditions
- First Posted Date
- 2007-01-25
- Last Posted Date
- 2010-09-14
- Target Recruit Count
- 100
- Registration Number
- NCT00426933
- Locations
- 🇺🇸
Idaho Falls Infectious Diseases, PLLC, Idaho Falls, Idaho, United States
Daptomycin as an Adjuvant Agent in the Treatment of Enterococcal Native Valve Endocarditis.
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2017-05-03
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 6
- Registration Number
- NCT00401960
- Locations
- 🇺🇸
NewYork-Presbyterian Hospital, Weill Cornell Campus, New York, New York, United States
Daptomycin in Treating Neutropenia and Fever in Patients With Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-06-12
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 54
- Registration Number
- NCT00335478
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Daptomycin or Vancomycin in Treating Bacteria in the Blood in Patients With Neutropenia Caused By Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2006-02-24
- Last Posted Date
- 2018-08-10
- Lead Sponsor
- Wake Forest University Health Sciences
- Registration Number
- NCT00296049
- Locations
- 🇺🇸
Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
Study Comparing CUBICIN® (Daptomycin for Injection) With Vancomycin in Cellulitis or Erysipelas
- Conditions
- First Posted Date
- 2006-02-23
- Last Posted Date
- 2017-09-07
- Target Recruit Count
- 80
- Registration Number
- NCT00295178
- Locations
- 🇺🇸
Joseph Still Research Foundation, Augusta, Georgia, United States
Study of Single Dose Daptomycin in Pediatric Patients With Gram-positive Infection for Which They Are Receiving Standard Antibiotics
- Conditions
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2020-03-11
- Target Recruit Count
- 33
- Registration Number
- NCT00136292
- Locations
- 🇺🇸
University of Texas Southwestern, Dallas, Texas, United States
🇺🇸Children's Mercy Hospitals and Clinics, Kansas City, Missouri, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Daptomycin in the Treatment of Subjects With Infective Endocarditis or Bacteremia Due to S. Aureus
- Conditions
Daptomycin for the Treatment of Infections Due to Gram-Positive Bacteria
- Conditions
- First Posted Date
- 2003-02-21
- Last Posted Date
- 2017-06-14
- Target Recruit Count
- 75
- Registration Number
- NCT00055198
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.